Kestra Medical Technologies’ (KMTS) Buy Rating Reiterated at BTIG Research

BTIG Research restated their buy rating on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $32.00 price target on the stock.

A number of other research analysts also recently issued reports on KMTS. Oppenheimer initiated coverage on Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating on the stock. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. JPMorgan Chase & Co. initiated coverage on Kestra Medical Technologies in a research report on Monday, August 10th. They issued an “overweight” rating and a $30.00 price objective on the stock. Wall Street Zen raised Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.14.

Kestra Medical Technologies Trading Up 1.6%

Shares of KMTS opened at $25.54 on Wednesday. The stock has a market capitalization of $1.50 billion, a P/E ratio of -10.55 and a beta of 0.62. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a fifty day simple moving average of $25.53 and a two-hundred day simple moving average of $22.78. Kestra Medical Technologies has a twelve month low of $16.68 and a twelve month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. On average, research analysts anticipate that Kestra Medical Technologies will post -2.29 EPS for the current year.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Alfred J. Ford, Jr. sold 6,275 shares of Kestra Medical Technologies stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $24.09, for a total transaction of $151,164.75. Following the completion of the transaction, the insider owned 99,564 shares in the company, valued at approximately $2,398,496.76. The trade was a 5.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vaseem Mahboob sold 26,287 shares of the business’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $25.88, for a total value of $680,307.56. Following the completion of the sale, the chief financial officer directly owned 60,609 shares in the company, valued at $1,568,560.92. This trade represents a 30.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 238,164 shares of company stock worth $5,700,952. Company insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Kestra Medical Technologies

Several large investors have recently modified their holdings of KMTS. Price T Rowe Associates Inc. MD grew its position in Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after purchasing an additional 2,529,851 shares during the last quarter. California State Teachers Retirement System raised its holdings in Kestra Medical Technologies by 2,366.0% in the second quarter. California State Teachers Retirement System now owns 686,422 shares of the company’s stock worth $17,463,000 after buying an additional 658,587 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Kestra Medical Technologies by 180.8% in the fourth quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock worth $25,221,000 after buying an additional 612,343 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Kestra Medical Technologies during the first quarter valued at approximately $11,036,000. Finally, Brown Advisory Inc. increased its position in shares of Kestra Medical Technologies by 34.1% during the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares in the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.